IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead
NXC-201, a novel CAR T therapy for AL amyloidosis, demonstrates rapid, deep responses and a favorable safety profile, with regulatory designations supporting accelerated review. A pivotal readout and BLA submission are expected, and a Phase III frontline trial is underway.Based on Immix Biopharma…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.